Danish pharmaceutical giant Novo Nordisk has expanded its obesity and metabolic disease pipeline through two major external acquisitions, securing non-incretin peptide candidates from Calliope Therapeutics and a macrocycle drug discovery platform from Orbis Medicines. According to corporate statements and industry reports from September 2026, the agreements arrive as the company works to diversify its portfolio following clinical setbacks in its late-stage pipeline and intensifying market competition from Eli Lilly.
Acquisition of Calliope Therapeutics Targets Non-Incretin Pathways
Novo Nordisk acquired three non-incretin obesity programs from U.S. biotechnology firm Calliope Therapeutics, according to a September 2026 announcement. The acquired assets include a first-in-class peptide candidate designated as K-554, a follow-on small molecule targeting a novel receptor, and a small molecule receptor agonist. Financial terms, exact targets, and commercialization rights were not disclosed by either company.
K-554 is a once-weekly peptide treatment designed to target non-incretin receptors that differ from GLP-1 and amylin pathways, according to Calliope Therapeutics data. The candidate utilizes biological pathways connecting the gut and the brain to transmit feelings of fullness without triggering nausea or aversion responses. While current incretin treatments like semaglutide and tirzepatide deliver significant weight loss, patients frequently face gastrointestinal side effects and weight regain after stopping treatment. K-554’s distinct mechanism suggests potential for monotherapy or combination use alongside existing incretin therapies, though the candidate remains in preclinical development with safety and efficacy yet to be proven in human clinical trials.
Orbis Medicines Agreement Advances Oral Macrocycle Platforms
One day prior to the Calliope announcement, Novo Nordisk entered into a licensing and discovery agreement with Danish biotech Orbis Medicines worth up to $1.4 billion in upfront, development, regulatory, and commercial milestones, alongside a strategic equity investment. The partnership focuses on discovering and developing oral macrocycle compounds directed at major cardiovascular and metabolic disease targets.
Macrocycles are molecules formed by large rings of atoms that can modulate protein-protein interactions—a task difficult for traditional small molecules—while maintaining oral bioavailability. Orbis utilizes its proprietary nGen platform and high-throughput chemistry screening to design nCycle macrocycles, with the core objective of converting injectable peptide and protein targets into oral medications. The $1.4 billion figure represents the maximum potential payout tied to all developmental and commercial milestones rather than an immediate cash transfer.
Portfolio Diversification Amid Pipeline Setbacks and Market Competition
Novo Nordisk’s aggressive external licensing strategy addresses the need to distribute risk across a broader range of therapeutic targets. The company recently discontinued development of a once-monthly GLP-1 candidate and halted a phase 3 trial for the interleukin-6 inhibitor ziltivekimab, which had been investigated for inflammatory cardiovascular and kidney diseases.
Simultaneously, Eli Lilly continues to challenge Novo Nordisk’s market dominance by advancing oral GLP-1 therapies and next-generation combination candidates. By partnering with Calliope and Orbis, Novo Nordisk aims to secure differentiated assets that reach beyond standard GLP-1 mechanisms and transition injectable treatments into oral formulations.
Key Takeaways
- Non-Incretin Pipeline: Novo Nordisk acquired three programs from Calliope Therapeutics, anchored by the K-554 peptide candidate, which targets gut-brain neural circuits independently of GLP-1 pathways.
- Oral Delivery Platform: The company partnered with Orbis Medicines in a deal valued at up to $1.4 billion to develop oral macrocycle compounds capable of converting injectable peptide targets into pills.
- Strategic Risk Management: The external asset acquisitions follow recent clinical discontinuations, including the termination of a once-monthly GLP-1 candidate and the ziltivekimab phase 3 program.
- Market Evolution: Global obesity drug development increasingly prioritizes combination mechanisms, reduced gastrointestinal side effects, muscle preservation, and improved patient convenience over pure weight-loss percentages.
Frequently Asked Questions
What is K-554?
K-554 is a once-weekly peptide candidate acquired from Calliope Therapeutics that targets non-incretin receptors to regulate food intake and satiety through distinct neural pathways.
What are macrocycle compounds?
Macrocycles are large ring-shaped molecules that can bind to complex protein targets while offering the potential for oral administration, effectively transforming drugs normally requiring injections into pills.
How much did Novo Nordisk pay for the Orbis Medicines partnership?
The agreement is valued at up to $1.4 billion, which includes an upfront payment, a strategic equity investment, and subsequent milestone payments tied to clinical development, regulatory approval, and commercialization success.
Keep reading